FU1- 3 month follow up | FU2- 6 month follow up | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Treatment | Control | Difference | p value | Treatment | Control | Difference | p value | |||
Adjusted outcomes | n | Mean (SE) | Mean (SE) | Mean (SE) | n | Mean (SE) | Mean (SE) | Mean (SE) | ||
SF-12 PCS | 71 | 39.07 (0.93) | 39.26 (0.97) | 0.19 (1.34) | .89 | 63 | 37.89 (0.94) | 38.44 (1.02) | 0.55 (1.39) | .70 |
SF-12 MCS | 71 | 42.43 (0.76) | 43.04 (0.80) | 0.61 (1.11) | .58 | 63 | 41.88 (0.85) | 42.91 (0.92) | 1.03 (1.26) | .42 |
EQ-5D Utility | 70 | 0.83 (0.02) | 0.81 (0.02) | −0.02(0.03) | .52 | 63 | 0.79 (0.02) | 0.84 (0.02) | 0.05 (0.03) | .12 |
EQ-5D VAS | 70 | 75.86 (2.05) | 74.04 (2.17) | −1.82 (2.99) | .57 | 63 | 74.41 (2.33) | 72.28 (2.52) | −2.14 (3.43) | .54 |